Kyle Gano - 12 Feb 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Executive Officer, Director
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
12 Feb 2026
Net transactions value
-$1,315,578
Form type
4
Filing time
17 Feb 2026, 17:48:20 UTC
Previous filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gano Kyle Chief Executive Officer, Director 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 17 Feb 2026 0001567160

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +4,907 +3.5% $0.000000 146,661 12 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $325,969 -2,648 -1.8% $123.10 144,013 12 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +2,241 +1.6% $0.000000 146,254 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $150,185 -1,210 -0.83% $124.12 145,044 13 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +2,566 +1.8% $0.000000 147,610 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $171,906 -1,385 -0.94% $124.12 146,225 13 Feb 2026 Direct F1
transaction NBIX Common Stock Award $0 +9,968 +6.8% $0.000000 156,193 13 Feb 2026 Direct F2
transaction NBIX Common Stock Tax liability $667,517 -5,378 -3.4% $124.12 150,815 13 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -4,907 -25% $0.000000 14,721 12 Feb 2026 Common Stock 4,907 Direct F3, F4
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,241 -33% $0.000000 4,484 13 Feb 2026 Common Stock 2,241 Direct F3, F5
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,566 -50% $0.000000 2,566 13 Feb 2026 Common Stock 2,566 Direct F3, F6
transaction NBIX Stock Option Award $0 +114,830 $0.000000 114,830 13 Feb 2026 Common Stock 114,830 $124.12 Direct F7
transaction NBIX Restricted Stock Unit Award $0 +20,142 $0.000000 20,142 13 Feb 2026 Common Stock 20,142 Direct F3, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
F2 On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
F3 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4 This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 4,907 shares on February 12, 2026, and will vest as to 4,907 shares on February 12, 2027, 4,907 shares on February 12, 2028, and 4,907 shares on February 12, 2029, subject to the terms and conditions of the award.
F5 This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award.
F6 This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award.
F7 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F8 The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.